3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
3
Neoplasms
3
Glioma
3
Triple Negative Breast Neoplasms
2
Sarcoma
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Prostatic Neoplasms
1
Paraproteinemias
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Interventions
Rituximab
23
Lenalidomide
11
Cyclophosphamide
10
zanubrutinib
9
Bendamustine Hydrochloride
8
venetoclax
6
ibrutinib
6
fludarabine
6
parsaclisib
5
idelalisib
5
ublituximab
4
obinutuzumab
4
aflibercept
4
Prednisone
4
pirtobrutinib
3
Vincristine
3
ME-401
3
Doxorubicin
3
umbralisib
2
tazemetostat
2
marizomib
2
epratuzumab
2
Radioimmunodetection
2
voruciclib
1
veltuzumab
1
varlilumab
1
tislelizumab
1
tetulomab tetraxetan lu-177
1
tafasitamab
1
repaglinide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, B-Cell, Marginal Zone
×
CLR1404
×
Clear all
NCT02952508
2026-03-18
CLOVER-WaM
Cellectar Biosciences, Inc.
Phase 2
Active not recruiting
120 enrolled